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Abstract
Purpose Pyruvate kinase deficiency (PKD) is a rare disease and understanding of its epidemiology and associated burden 
remains limited. With no current curative therapy, clinical manifestations can be life threatening, clinically managed by main-
taining adequate hemoglobin levels through transfusion and subsequent support, but with frequent complications. Treatment 
goals are to maintain/improve the patient’s quality of life. With new therapies, reliable, valid, and relevant patient-reported 
outcome (PRO) tools are required for use in clinical trials.
Methods Systematic literature search identified no current PRO tools for capturing/measuring the impact of PKD and 
treatments in clinical trials. Therefore, the search strategy was revised to consider conditions analogous to PKD in terms of 
symptoms and impacts that might serve as parallels to the experience in PKD; this included sickle cell anemia, thalassemia, 
and hemolytic anemia. Psychometric properties, strengths, and weakness of selected appropriate PRO instruments were 
compared, and recommendations made for choice of PRO tools.
Results In adult populations, EORTC QLQ C30 and SF-36v2 are recommended, the former being a basic minimum, cover-
ing generic HRQoL, and core symptoms such as fatigue. In pediatric populations, PedsQL Generic Core Scale to measure 
HRQoL and PedsQL MFS scale to measure fatigue are recommended.
Conclusions Some symptoms/life impacts may be unique to PKD and not observable in analogous conditions. A ‘Physico-
Psychosocial Model’ derived from the ‘Medical Model’ is proposed to form the basis for a hypothesized conceptual frame-
work to address the development of PKD-specific PRO instruments.
Keywords Pyruvate kinase deficiency · Patient-reported outcome · PRO · Quality of life
Introduction
Pyruvate kinase deficiency (PKD) is the most common cause 
of chronic non-spherocytic hemolytic anemia (CNSHA), 
and is inherited as an autosomal recessive trait [1]. PKD 
is regarded as a rare disease, with gene frequency studies 
estimating prevalence of 1 per 20,000 persons in the white 
population [2]. Understanding of the epidemiology and bur-
den associated with PKD remains limited, due to the low 
incidence of the condition. Clinical manifestations of the 
condition may include chronic mild or fully compensated 
anemia to life-threatening neonatal hemolysis requiring 
exchange transfusions and subsequent transfusion support 
[3]. Neonatal jaundice is common. In adults, the degree of 
anemia seems to be relatively constant, with exacerbations 
during acute infections and pregnancy [3]. Consequently, 
the disease is associated with significant negative impact on 
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a patient’s quality of life (QoL). Thus, frequent complica-
tions of PKD include aplastic crises, extramedullary hemat-
opoiesis, pregnancy complications of affected mothers, 
and need for exchange transfusion in the newborn period. 
Increasing severity of PKD (based on frequency of transfu-
sion) has been associated with a trend of increasing ferritin 
and liver iron concentration [4].
There is currently no curative therapy for PKD, and the 
condition is clinically managed by maintaining adequate 
hemoglobin levels through transfusion and using splenec-
tomy for patients with severe anemia or symptomatic hyper-
splenism [1, 5–7], both resulting in a marked increase of 
patient morbidity and mortality. Although hematopoietic 
stem cell transplantation may offer a cure for PKD, this has 
yet to demonstrate favorable benefit-risk balance, and is cur-
rently not standard practice [8]. Iron overload, in part due to 
chronic blood transfusions, often necessitates treatment with 
iron chelation therapy, which has been reported to result in 
various complications in nearly a quarter of patients receiv-
ing chelation [9]. Thus, the treatment goal for PKD is to 
maintain/improve the patient’s QoL.
An investigational therapy of AG-348, a small mol-
ecule allosteric activator of WT red cell pyruvate kinase, 
which directly addresses the underlying pathology of PK 
deficiency, is undergoing clinical development [10]. This 
new agent has potential to significantly improve a patient’s 
QoL. In addition, gene therapy offers promise as a safe 
and efficient treatment modality [11–14], similar to that of 
genetic correction for other diseases such as β-thalassemia 
in humans [15].
With the advancement of new therapies and trials, there 
is thus a need to identify reliable, valid, and relevant patient-
reported outcome (PRO) tools for use in planned clinical tri-
als. This paper presents a systematic search of the literature 
to identify current PRO tools that may be used to capture/
measure the impact of PKD and its treatment in clinical tri-
als. It aimed to (1) identify appropriate PRO instruments, 
based on analogous diseases with similar symptoms, and 
compare their psychometric properties, strengths, and weak-
nesses; (2) build a ‘Physico-Psychosocial Model’ for PKD; 
and (3) provide recommendations for the choice of PRO 
tools for use in future clinical trials.
Materials and methods
The approach employed in this study involved three steps. 
First, understanding how patients experience symptoms and 
impacts associated with PKD. Second, developing a hypo-
thetical conceptual framework for relevant PRO concepts in 
PKD and, finally, identifying the appropriate PRO measures 
for assessing such concepts.
The literature searches were performed in two stages. 
Initially, searches were carried out for literature reporting 
results on PROs in PKD. Secondly, studies reporting key 
evidence on the development or validation of the most fre-
quently used PRO measures were searched. Initial MED-
LINE searches for studies reporting PROs in PKD (using 
the search terms in Table 1, block 1 and block 2) yielded 
no relevant results, and therefore the search strategy was 
revised to consider conditions analogous to PKD in terms of 
symptoms and impacts, which might serve as parallels to the 
experience in PKD; this included sickle cell anemia, thalas-
semia, and hemolytic anemia. Records identified, screened, 
excluded and included, and extracted for final analysis are 
shown in the flow chart in Fig. 1.
Thalassemia, sickle cell anemia, and PKD all give rise 
to splenomegaly, which results in symptoms of abdominal 
pain [16], chest pain [16], and anemia due to accompanying 
cytopenia in these diseases. All three diseases also give rise 
to hemolytic anemia resulting in symptoms of fatigue [17] 
Table 1  Key terms used for literature searches
Block 1 Pyruvate kinase deficiency
Block 2 Quality of life; functional status; health status; functional impairment; functional limitations; activities of daily living
Records identified through 
Pubmed MEDLINE (n = 267)
Abstracts screened for 
relevance (n = 41)
Full-text articles 
reviewed (n = 25)
Studies extracted 
(n = 16)
Titles not relevant:226
Abstracts excluded: 16
Disease not relevant; No 
outcomes of interest 
Fig. 1  Flow diagram of studies in the literature review process, for 
the revised searches based on conditions analogous to pyruvate 
kinase deficiency
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and shortness of breath [18], sleep disturbances [19, 20], 
and jaundice [16, 17]. As a result of blood transfusions used 
as a treatment in these three diseases, iron overload occurs, 
resulting in heart [21, 22] or liver disease [22, 23], infections 
[16], and osteoporosis [24, 25]. Leg ulcers are another com-
plication of all three diseases [16, 21, 26]. Finally, thalas-
semia can give rise to bone deformities [27], sickle cell dis-
ease to avascular necrosis of the bone [28], and PKD to joint 
pain [16]. It is these symptoms and their impacts that reduce 
patients’ reported reduction in quality of life, and thus it is 
very appropriate to use these analogous diseases to serve as 
parallels to the experience in PKD.
Following the development of a hypothetical conceptual 
framework and the identification of possible PRO measures, 
pragmatic searches were then carried out to identify psycho-
metric attributes of the identified PROs. A short description 
of each tool is given in the supplementary data.
Results
Symptoms and health‑related quality of life issues
No studies were found reporting symptoms or life impacts 
in PKD, except for a protocol of an ongoing observational 
study registered in a clinical trials database (https ://clini caltr 
ials.gov). This study (NCT02053480), aimed at describ-
ing the range and symptoms, treatment, and complications 
related to PKD is underway in the USA at the Children’s 
Boston Hospital [29]. The study includes patients of all ages 
diagnosed with PKD, or patients with hemolytic anemia and 
a family member with genetically diagnosed PKD. The pri-
mary outcome was transfusion burden, while the second-
ary outcomes were patient-reported outcomes assessed on 
various measures such as the EuroQoL-5D-5L, Functional 
Assessment of Cancer Therapy-Anemia (FACT-An), Pedi-
atric Quality of Life Inventory 4.0 (pedsQL 4.0), Pediatric 
Functional Assessment of Chronic Illness-Fatigue (peds-
FACIT-F), and Patient-Reported Outcomes Measurement 
Information System Fatigue (PROMIS Fatigue).
Three qualitative studies describing the experience of 
patients with sickle cell disease (SCD) and patients receiv-
ing infusion iron chelation therapy provided insights into 
the possible patient-reported outcomes (PROs) in PKD. In 
addition, results from patients with chronic kidney disease 
(CKD)-related anemia are reported.
In another qualitative study, Stegenga et al. [30] explored 
the QoL of children with SCD aged 6–12 years (n = 10) 
receiving chronic transfusion therapy for stroke, using semi-
structured interviews. Five themes reflecting the concerns of 
the children emerged from their data, including physical and 
psychological pain; school issues, i.e., attendance and being 
treated differently by teachers and peers; disease knowledge; 
transfusion therapy; and having a stroke. The authors men-
tioned that the children did not distinguish between disease 
and treatment-related aspects. In addition, given the sample 
size it is unclear whether these findings are generalizable.
Further, the experiences of adolescents and young adults 
with SCD, aged 15–35 years, have been reported by Thomas 
and Tylor [31], based on focus groups with patients (n = 17). 
Patients reported impacts in six major areas including grow-
ing up with SCD, education, the recurrent nature of the dis-
ease, employment, relationship, and hospitalization. The 
authors concluded that the aspects of life affecting SCD 
were equivalent to the core domains of the multidimensional 
WHOQOL including physical, psychological, social, and 
occupational and well-being, as well as levels of independ-
ence and environment.
In addition to direct disease impacts, complications such 
as iron overload are also of particular interest, especially 
due to the adverse consequences of iron chelation therapy. 
The QoL impacts of iron overload and infusion iron chela-
tion therapy have been investigated by Abetz and colleagues 
[32] based on literature review and interviews with patients 
and experts.
The authors found no literature focusing on the impact 
of iron overload or iron chelation therapy on QoL, although 
this was reported incidentally in a few papers. In one study, 
50% of patients reported that daily activities were negatively 
affected (prevented) due to desferoxamine treatment. Iron 
chelation therapy (ICT) with desferoxamine was associated 
with a degree of discomfort resulting in limitations in daily 
life activities. Characteristics of the infusion such as higher 
frequency also resulted in HRQoL impairment.
Results from the interviews with patients (thalassemia, 
sickle cell disease, myelodysplastic syndromes) performed 
by Abetz et al. [32] were consistent with the current lit-
erature as reported above. HRQoL impact was particularly 
profound where treatment started from a young age and 
persisted throughout life, for example in thalassemia. In 
addition to effects experienced by the patients, the impacts 
on family/parents of pediatric patients included paren-
tal stress, related to daily inserting of a needle into their 
child, and strain on the relationship between parent–child 
(family–patient). Adolescents experienced impacts on self-
image, were unable to wear certain clothes, and felt embar-
rassed to go out as a result of bumps/bruises on their skin. 
Adults reported impacts on work, sex life, and social life. 
The impact of ICT on QoL was noted to be greatest among 
adolescents and young adults. These results suggest that 
infusion ICT has substantial impacts across multiple QoL 
domains. It is still unclear whether similar impacts are expe-
rienced in patients treated with other ICT.
Lasch et al. [33] investigated how adults with chronic 
kidney disease on dialysis experienced the symptoms of 
anemia, using semi-structured interviews with 55 patients. 
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Their data revealed 20 major themes including energy, tired-
ness, endurance, shortness of breath, strength/weakness, and 
needing more sleep. Themes associated with the impacts of 
anemia included need to move slower; feeling bad/better; 
restless sleep; and effort required for exercise. Lasch and 
colleagues commented that all symptoms/impacts reported 
by the patients could be tied to a symptom cluster related 
to energy. The authors further mentioned that the patients 
related the energy symptoms cluster to rising and falling of 
hematocrit levels.
Further, in addition to the qualitative evidence presented 
above, five studies applying quantitative methods, using 
generic HRQoL measures such as the SF-36, EORTC QLQ 
C30, FACIT-fatigue, and PedsQL Generic Core Scale, 
showed reduced HRQoL across multiple domains, and 
increased levels of fatigue.
McClish et al. [34] assessed QoL in adults with SCD 
(n = 308) participating in the Pain in Sickle Cell Epidemi-
ology Study (PiSCES) in the US. SF-36 scores indicated 
worse HRQoL relative to US national norms on all subscales 
except mental health. In comparison with dialysis patients, 
adults with SCD scored similarly on physical role and emo-
tional role function, social functioning and mental health, 
worse on bodily pain, general health and vitality, and better 
on physical functioning. In comparison with people with 
cystic fibrosis, adults with SCD showed worse SF-36 scores 
on all subscales except mental health.
Dampier et al. [35] investigated HRQoL in children with 
SCD using data from the Collaborating Project of the Com-
prehensive Sickle Cell Centers (CSCC) clinical trial con-
sortium, employing the PedsQL scales (Generic Core scale/
Multidimensional Fatigue scale). Their results showed a pro-
gressive decline in all parent-reported PedsQL scale scores 
(physical, emotional, school functioning, total HRQoL, gen-
eral fatigue, sleep/rest fatigue, total fatigue) across younger 
to older age groups (except for cognitive fatigue). Similar 
decline was observed in child-reported PedsQL scale scores 
(physical, emotional, social, school functioning, sleep/rest 
fatigue, cognitive fatigue scales). Parents and children 
differed on the rating of social functioning and cognitive 
fatigue, and on the overall, PedsQL scores; child reports 
were higher than parent reports. In comparison with age-
matched healthy children, children with SCD showed much 
lower PedsQL scores (lower HRQoL and higher fatigue). 
The authors attributed the gradual but significant decline in 
HRQoL to acute and chronic complications (such as vaso-
occlusive pain or priapism) which increased in frequency 
over time.
Ameringer et  al. [36] recently described fatigue and 
its key biological and behavioral correlates, as well as its 
relationship with HRQoL, in adolescents and young adults 
with SCD (n = 60) aged 15–30. The majority of adolescents 
and young adults (69%) reported feeling unusually tired or 
fatigued in the previous week, and scores of various fatigue 
scales (MFSI-SF, PROMIS Fatigue) showed mild to moder-
ate fatigue. Levels of fatigue did not differ by disease sever-
ity or biomarkers of inflammation. The correlation of hemo-
globin and fatigue depended on the scale used for measuring 
fatigue. Higher fatigue was correlated (r = 0.31–0.70) with 
increased anxiety, pain, and sleep disruptions. Fatigue scales 
showed a moderate correlation with all subscales of the 
SF-36 (r = − 0.34 to − 0.74).
In thalassemia, HRQoL impairment similar or worse 
than that in SCD has been reported due to need for chronic 
transfusion and chelation therapy. A study by Sobota et al. 
[37] compared HRQoL reported in the Thalassemia Clinical 
Research Network’s Longitudinal Cohort (TLC) (n = 264, 
age ≥ 14) to US norms and published literature. In compari-
son to the US norms, TLC patients showed worse HRQoL 
on five of eight SF-36 subscales (physical functioning, role-
physical, general health, social functioning, and role-emo-
tional) and on both summary scales (physical and mental 
components). The greatest effect was in general health and 
physical domains. Women, older patients, and those with 
more disease complications and side effects from chelation 
reported lower HRQoL.
Further, Sobota and colleagues [37] argued that their 
results were similar to results obtained from two earlier stud-
ies of Payne et al. [38, 39] which reported lower age/gender-
matched scores for all SF-36 domains in patients with thalas-
semia in comparison with UK norms. However, Sobota et al. 
[37] reported contrasting results from two studies from Italy, 
one reporting that scores in thalassemia patients were not 
much different from Italian SF-36 score norms. The other 
study reported that patients showed lower scores only for 
social functioning, role-emotional and mental component 
summary. Sobota and colleagues [37] argued that the older 
age of patients in the Italian studies explains the contrasting 
results.
Schrezenmeier et al. [40] reported the initial findings 
from the international Paroxysmal Nocturnal Haemoglo-
binuria (PNH) registry observational study (n = 1610) 
to describe clinical characteristics and disease-associ-
ated comorbidities in this patient population. Half of 
the patients were diagnosed with bone marrow disorder 
including aplastic anemia, hypoplastic anemia, myelod-
ysplastic syndromes, myelofibrosis, and/or acute myeloid 
leukemia. The most common symptoms included fatigue 
(80%), dyspnea (64%), headache (63%), hemoglobinuria 
(62%), abdominal pain, scleral icterus, erectile dysfunc-
tion, chest pain, confusion, and dysphagia. Scores for all 
EORTC QLQ C30 domains were statistically significantly 
lower (i.e., lower HRQoL) for patients who had reported 
a clinical symptom of abdominal pain, chest pain, confu-
sion, dysphagia, dyspnea, erectile dysfunction, fatigue, 
headache, hemoglobinuria, or scleral icterus in the six 
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months prior to completing the baseline questionnaire 
compared with patients who had not experienced the 
symptoms.
Physico‑psychosocial model for pyruvate kinase 
deficiency
Based on the evidence of symptoms and impairment in 
PKD analogous conditions, the possible patient-reported 
symptoms and impacts expected in PKD were hypoth-
esized (Fig. 2).
Based on the major clinical features of PKD, i.e., ane-
mia, iron overload, acute infections, and splenomegaly, 
the broad areas of patient outcomes include symptoms, 
HRQoL impacts, treatment-related impacts, and fam-
ily life impacts. The key symptoms in PKD are likely to 
be related to anemia, jaundice, and splenomegaly, and 
include fatigue, sleep disturbances, abdominal pain, chest 
pain, shortness of breath, and depression. The require-
ment for chronic treatment, e.g., chronic blood transfu-
sion, and iron chelation, from an early age is associated 
with substantial treatment burden, which includes the 
time/effort required to manage treatments, the physical 
discomfort associated with treatment, and the side effects 
of treatment. Ultimately, disease symptoms and treat-
ment burden result in impairment in multiple domains 
of HRQoL including daily activities, psychological func-
tioning, self-image, physical functioning, and social life. 
The substantial impacts on HRQoL and the treatment 
burden, consequently, have an impact on the family as a 
whole (these may be exaggerated for pediatric patients but 
are otherwise equally important for all patients).
HRQoL measures
The most frequently used measures in PKD/PKD analogous 
conditions that address concepts in the hypothesized Phys-
ico-Psychosocial model outlined in Fig. 2 were searched. A 
total of 11 PRO measures, 1 disease-specific measure, and 1 
generic family life impact measure were identified. The EQ-
5D-5L was excluded as it was considered to be more appro-
priate for evaluating utilities for the purposes of economic 
evaluation, and less fitting for capturing treatment effect in 
trial settings, and FACIT-Fatigue excluded as a stand-alone 
measure, as its contents are already included as the fatigue 
scale in the FACT-An. Details of each measure are given in 
the Supplementary Data.
The PRO measures were evaluated against standards pub-
lished in the FDA PRO guidance [41]. In brief, the adequacy 
of any PRO measure to support medical product labeling 
claims depends on its characteristics, conceptual, content 
validity, and measurement properties. A comparison of the 
content coverage is reported in Table 2, while an evaluation 
of the psychometric attributes is presented in Table 3.
Appraisal of HRQoL measures
Adults
Four most relevant QoL/HRQoL measures used in patient 
populations analogous to PKD patients, the WHOQOL-
BREF, the SF-36, the EORTC QLQ C30, and the FACT-
An were compared (Table 4). Of these four, the EORTC 
QLQ C30 addressed all impact as well as symptom con-
cepts except for “self-image” (Table 2). The WHOQOL-
BREF, although based on a more broad definition of 
Fig. 2  Pyruvate kinase defi-
ciency physico-psychosocial 
model
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health, has psychometric evidence that supports using this 
scale for adults with chronic conditions and addresses the 
individualized nature of HRQOL, so is appropriate for 
this purpose [55]. The SF-36 and the FACT-An (particu-
larly the FACT-G subscale) address similar impact-related 
concepts, except for one concept “perceived general 
health/HRQoL” which is assessed in the SF-36 only. The 
WHOQOL-BREF and the SF-36 address most domains 
with greater detail in comparison with the FACT-An, i.e., 
with more items addressing a wider range of issues. For 
example, whereas the FACT-An contains 2 items directly 
related to work, the SF-36 has 7 items/2 subscales to rep-
resent this issue. The FACT-An covers four of the five key 
symptom concepts, excluding “depression”; the SF-36 
addresses three symptom concepts, while the WHOQOL-
BREF covers two only. The “shortness of breath” and 
“sleep disturbances” concepts have been excluded from 
the WHOQOL and SF-36.
Extensive psychometric evidence including construct 
validity, reliability, and responsiveness is available sup-
porting the validity of the EORTC QLQ C30, SF-36v2, 
and FACT-An measures in PKD analogous conditions 
such as sickle cell and cancer-treatment-related anemia.
Pediatric/adolescents
Comparison of HRQoL measures used in pediatric patients 
considered the Children’s Health Questionnaire (CHQ) 
and the PedsQL 4.0 Generic Core Scales (Table 4). The 
CHQ appeared to have better coverage of impact-related 
concepts in comparison with the PedsQL 4.0, in particu-
lar the “impact on self-image,” “perceived general health/
HRQOL,” and “family impacts.” For symptom-related 
concepts, the CHQ addresses one concept, while the Ped-
sQL 4.0 Generic score includes none. Such an omission in 
the PedsQL Generic Core Scale may be due to the avail-
ability of a SCD-specific PedsQL module, which seemed 
to be the most validated SCD-specific instrument in the 
pediatric population (Table 4).
Although most subscales of the CHQ apply a recall 
period of 4 weeks, one subscale (change in health) uses 
a recall period of 1 year. Long recall periods are gener-
ally not recommended due to concerns about accuracy of 
recall and potential biases. On the other hand, as assess-
ment of HRQoL occurs at a certain interval within a study, 
assessing differences between such “actual” snapshots of 
Table 3  Evaluation of psychometric attributes of PRO measures
SF-36 short-form medical outcome, WHOQOL-BREF WHO Quality of Life-BREF, FACT-An functional assessment of cancer therapy-anemia, 
EORTC QLQ C30 European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, FROM-16 Family-
Reported Outcome Measure-16, PedsQL Pediatric Quality of Life Inventory, MFS Multidimensional Fatigue Scale, SCD sickle cell disease, 
pedsFACIT-F pediatric Functional Assessment of Chronic Illness Therapy-Fatigue, CHQ Children’s Health Questionnaire, ASCQ-Me adult 
sickle cell quality of life measurement information system, ++: adequate data available from PK-d analogous population, +: data are available 
from PK-d analogous population, although inadequate, 0: data available in other patient populations, but not from PK-d analogous populations, 
−: data not reported in any patient population
a For the FACT-G and FACT-F subscales
Content 
validity
Construct 
validity
Internal 
consist-
ency
Test–retest Responsiveness MCID Respondent burden; 
completion time
Language translations
SF-36 0 ++ ++ 0 + 0 Minimal; 5–10 min > 170 countries
WHOQOL-BREF ++ ++ ++ + 0 0 Minimal; < 5 min > 23 countries (cul-
tural adaptations)
FACT-An ++ ++ ++ ++ ++ ++ Minimal; 5–15 min > 45  languagesa
EORTC QLQ C30 ++ ++ ++ ++ ++ ++ Minimal 5–15 min > 80 languages
FROM-16 ++ ++ ++ ++ ++ − Minimal; < 3 min 2 languages
PedsQL 4.0 
Generic Core 
Scale
+ ++ ++ ++ ++ ++ Minimal; < 4 min > 21 languages
PedsQL 4.0 MFS + ++ ++ ++ ++ ++ Minimal; < 4 min > 21 languages
PedsQL SCD ++ ++ ++ ++ ++ ++ Minimal; < 4 min –
pedsFACIT-F ++ ++ ++ − − ++ 5–10 min –
CHQ 0 ++ ++ 0 0 0 5–15 min > 72 languages
ASCQ-Me ++ ++ ++ − − − ~ < 10 min –
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the patients’ conditions provides the most reliable way of 
assessing change over time.
For the assessment of fatigue, two measures, the PedsQL 
MFS and the pedsFACIT-F, were compared (Table 4). Both 
measures address multiple dimensions of fatigue includ-
ing physical as well as psychological aspects, although the 
PedsQL MFS additionally includes sleep aspects. More 
psychometric evidence is available for the PedsQL MFS 
relative to the pedsFACIT-F; specifically evidence of the 
pedsFACIT was not available.
For family life impacts, the Family-Reported Outcome 
Measure (FROM-16) was the only measure considered 
across the pediatric, adolescent, as well as adult patient 
populations (Table 4). This measure has been validated for 
Table 4  Appraisal of health-related quality of life measures
Attribute Advantages Disadvantages
SF-36 • The most widely used PRO measure in general in PKD 
analogous conditions
• Floor/ceiling effects for some subscales (e.g., PH) in SCD
• Published dimensional structure not supported in SCD (a 3 
component structure was reported in a Jamaican popula-
tion)
• Content validity in SCD not demonstrated
WHOQOL-BREF • Cross-culturally developed • Measures relatively broader and subjective QOL domains, 
which may be affected by other factors unrelated to PK-d 
treatment
• Limited regulatory experience
FACT-An • Extensive regulatory experience based on clinical trials of 
ESAs in cancer patients
• Integrates generic HRQOL aspects as well as impacts/
symptoms specific to anemia
EORTC QLQ C30 • Has best coverage of impacts/symptom-related concepts 
for the psychosocial model
• Extensive regulatory experience based on clinical trials of 
ESAs in cancer patients
• Integrates generic HRQOL aspects relevant to anemia
CHQ • Domain structure is different between healthy children and 
those with a chronic disease
• Use of multiple response scaling and recall periods has 
potential to be confusing
PedsQL • Has the most extensive psychometric evidence in pediatric 
SCD
• Has been used to support a PRO labeling claim for Soliris 
in PNH in Europe
• Recall period and response scaling appropriate for pedi-
atrics
PedsQL MFS • One of the most validated and widely used pediatric 
fatigue measures in SCD
• Has been used to support a PRO labeling claim for Soliris 
in PNH in Europe
PedsQL SCD • Content is underpinned by extensive qualitative research 
across children 5–8 years, parents, and experts in SCD
• Provides comprehensive measurement capabilities in com-
bination with other PedsQL scales (i.e., generic, fatigue)
• As the measure is relatively new, current psychometric 
evidence is not extensive
• Some scales could not discriminate between mild-severe 
disease for child report
pedsFACIT-F • Superior measurement attributes—its development 
applied modern test theory
• May permit possible comparison with scores from adult-
version FACIT-F
• Some key psychometric properties have not been reported, 
e.g., responsiveness and test–retest reliability
• Clinical trials using the measure were scarce
• Regulatory uncertainty with use of PROs based on item 
banks in drug development
ASCQ-Me • The only item bank for ASCQ-Me
• High precision/strong measurement capabilities as a result 
of use of modern test theory as well as classical test theory
• Regulatory uncertainty with use of PROs based on item 
banks in drug development
FROM-16 • Rigorous development and validation across at least ten 
medical specialties
• High precision/strong measurement capabilities as a result 
of use of modern test theory as well as classical test theory
• As the measure is quite new, use in clinical trials remains 
limited
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use across all disease areas, and in all patient populations. 
There is to date limited use of this measure in clinical trials, 
reflecting the novelty of the conceptualization of family life 
impact as a broad and generic concept. Other measures such 
as the Family Dermatology Life Quality Index (FDLQI) or 
the PedsQL Family Impact Module were not reviewed, as 
they were considered to be too narrowly focused on a spe-
cific disease/patient population.
Discussion
The PRO instruments potentially useful in PKD trials have 
been identified and their psychometric properties, namely 
strengths and weaknesses, were compared. On this basis, 
recommendations for the choice of PRO tools for use in 
future clinical trials are provided here. The relevance of PRO 
measures for use in PKD trials has been evaluated based 
on the understanding that clinical trials may include adult 
patient populations as well as pediatrics and adolescents. 
These conclusions therefore address the outcome measure-
ment’s unique requirements of these groups.
Relevant patient-reported outcomes (PROs) in PKD 
encompass disease-specific symptoms, generalized impacts 
on multiple HRQoL domains and impacts on the wider 
family; this is the case for pediatrics, adolescents, as well 
as adult patient populations. Therefore, all these areas of 
impact should be measured in Phase II and III trials. Thus, 
measures addressing generic HRQoL, disease-related 
symptoms (particularly anemia-related symptoms such as 
fatigue), and family impacts should be considered.
In the adult population, the uses of EORTC QLQ C30 
and SF-36v2 are recommended, the former being the basic 
minimum, particularly because this measure covers all key 
impacts as well as symptom concepts in the hypothesized 
physico-psychosocial model, including generic HRQoL, as 
well as core symptoms such as fatigue. It would be beneficial 
to use SF-36v2 in a study to validate results from EORTC 
QLQ C30, as well as to facilitate further comparative 
research in PKD, with other similar/related diseases. The 
SF-36v2 would be a better additional generic PRO measure 
than WHOQOL-BREF based on extensive experience with 
the SF-36 in clinical trials across PKD analogous conditions 
and a lack of such evidence with the WHOQOL-BREF.
In the pediatric population, the uses of PedsQL Generic 
Core Scale and the PedsQL MFS scale are recommended. 
The PedsQL Generic Core Scale is recommended as a meas-
ure of HRQoL, over the CHQ. The PedsQL MFS scale is 
recommended as a measure of fatigue over the pedsFACIT.
For pediatrics, adolescents, as well as the adult patient 
populations, the FROM-16 is recommended for the meas-
urement of family burden associated with PKD. At present, 
this is considered to be the only generic measure of family 
life impact of illness appropriate for use across different 
patient populations. For example, the PedsQL has a family 
life impact module; however, this may not be of use in an 
adult population. Inclusion of this measure may be more 
appropriate for Phase III trials.
As currently no PRO measure has been validated in PKD, 
we recommend exploratory qualitative research to gener-
ate required content validity evidence (in a form of a pilot 
study) to support the above-recommended measures in PKD. 
Furthermore, we recommend that the blinded data from the 
phase II trial be utilized to assess/confirm the validity, reli-
ability, responsiveness, and MCID of the recommended 
measures in PKD.
Thalassemia and paroxysmal nocturnal hemoglobinu-
ria are clearly analogous to PKD, but sickle cell disease is 
a much more complicated disorder. The pathophysiology 
of sickle cell disease, in particular vaso-occlusive crises, 
is very different from what occurs in PKD. However, the 
selected PRO tools measure the impact of the disease and 
treatments from patient’s perspectives, and the analogous 
diseases chosen have symptoms that will produce similar 
patient experiences, even if the pathophysiology of the dis-
ease is somewhat different and some symptoms are different.
A major limitation to the above recommendations is that 
it is not possible to determine which symptoms/life impacts 
seen in the PKD analogous conditions may actually be 
observed in patients with PKD. Similarly, it is likely that 
some symptoms/life impacts in PKD are unique to the dis-
ease, and are not observable in analogous conditions, for 
example aplastic crises, osteopenia/bone fragility, extramed-
ullary hematopoiesis, post-splenectomy sepsis, pulmonary 
hypertension, and leg ulcers [56]. Therefore, it would be 
ideal, at the minimum, to obtain the views of therapeutic 
experts on key symptoms and life impacts. A patient diary 
may then be developed within a short-time framework, to 
address those symptoms/life impact not covered in the cur-
rent PRO measures, based on expert input. Social network-
ing communities of patients with PKD may also be used to 
rapidly develop and validate such a diary.
The developed Physico-Psychosocial model for PKD 
may be helpful in future studies with a PRO component in 
patients with PKD. It may also form the basis for a hypoth-
esized conceptual framework to be used for the development 
of a disease-specific PRO tool to capture/measure the QoL 
and symptom impact of PKD and its treatments in clinical 
trials.
At this stage, it is not possible to use empirical testing, 
e.g., structural equation modeling (SEM)/path analysis 
on this Physico-Psychosocial model for PKD. As there is 
currently no tool in this population, the data that we used 
came from variety of non-PKD tools for analogous diseases, 
applied in different settings. Therefore, this model should be 
a starting point to guide the next step to develop a specific 
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Pyruvate Kinase Deficiency tool. Then, through data collec-
tion using this tool in a PKD population, it will be possible 
to test and either confirm or refute this Physico-Psychosocial 
Model.
Additionally, as the data used for this review came from 
a range of tools for analogous diseases, with a high level 
of heterogeneity among the different studies, it does not 
lend itself to meta-analysis and determination of effect size. 
Although the Pyruvate Kinase Deficiency Natural History 
Study (PKD NHS, https ://clini caltr ials.gov, NCT02053480), 
a longitudinal, multicenter, international patient registry, is 
collecting retrospective and current clinical information and 
patient-reported outcome measures at enrolment and annu-
ally (expected study completion Dec 2020), there are limited 
data from PRO studies on PKD and quality of life. Until 
more data are available, effect size remains unknown.
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Glossary
Allosteric activator  Binding of one ligand 
enhances the attraction 
between substrate molecules 
and other binding sites
Aplastic crises  Temporary cessation of red 
cell production
Autosomal recessive trait  Ways that a trait, disorder, or 
disease can be passed down 
through families whereby 
two copies of an abnormal 
gene must be present in 
order for the disease or trait 
to develop
β-Thalassemia  A genetic blood disorder 
that reduces the production 
of hemoglobin
Chelation Therapy  A form of complementary 
therapy involving circulating 
a chelating solution in the 
bloodstream to bind toxins
Chronic non-spherocytic  
hemolytic anemia  A group of rare, genetically 
transmitted blood disorders 
characterized by the pre-
mature destruction of red 
blood cells
Cytopenia  Reduction in the level of red 
blood cells
Desferoxamine  A medication that binds iron 
used to treat iron overload
Extramedullary  
hematopoiesis  Hematopoiesis (differentia-
tion processes that lead to 
the formation of all blood 
cells from hematopoietic 
stem cells) occurring in 
organs outside of the bone 
marrow
Hematopoietic stem  
cell transplantation  Is the transplantation of 
multipotent hematopoietic 
stem cells
Hemolytic anemia  A form of anemia due to 
hemolysis, the abnormal 
breakdown of red blood cells
Myelodysplastic syndromes  A group of cancers in which 
immature blood cells in the 
bone marrow do not mature 
and therefore do not become 
healthy blood cells
Neonatal hemolysis  Hemolytic disease of the 
newborn
Neonatal jaundice  A yellowish discoloration 
of the white part of the eyes 
and skin in a newborn baby 
due to high bilirubin levels
Paroxysmal nocturnal  
hemoglobinuria  A rare blood condition 
where blood cells are prone 
to be attacked by part of the 
body’s immune system
Pathophysiology  Functional changes associ-
ated with or resulting from 
disease or injury
Post-splenectomy sepsis  Body’s response to infection 
causing injury to its own tis-
sues and organs following 
removal of the spleen
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Pulmonary hypertension  Increased blood pressure 
within the arteries of the 
lungs
Pyruvate kinase  The enzyme that catalyzes the 
final step of glycolysis
Structural equation modeling  A diverse set of math-
ematical models, computer 
algorithms, and statistical 
methods that fit networks 
of constructs to data and 
includes confirmatory factor 
analysis, path analysis, and 
partial least squares
Symptomatic  
hypersplenism  Exhibiting an overactive 
spleen, removing too many 
blood cells, including 
healthy ones
Path analysis  An extension of multiple 
regression used to provide 
estimates of the magnitude 
and significance of hypoth-
esized causal connections 
between sets of variables and 
includes multiple regression 
analysis, factor analysis, and 
discriminant analysis
Vaso-occlusive crises  A common painful compli-
cation of sickle cell anemia 
where circulation of blood 
vessels is obstructed by sick-
led red blood cells, causing 
ischemic injuries
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